NextPoint Therapeutics

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway.

[NextPoint Therapeutics @NextPointTX]

Executive Director
Matthew Rausch, PhD, is presenting a poster atSITC Spring Scientific meeting. The poster explores the biology of the B7-H7 pathway and its potential to enhance T-cell–mediated anti-tumor responses. Reach out if you want to connect! #SITC

[NextPoint Therapeutics @NextPointTX]

#InternationalWomensDay may have passed, but we’re still celebrating the women whose expertise and leadership drive our work at NextPoint. A snapshot of the people behind the science advancing precision immuno-oncology.
#WomenInScience #WomenInBiotech

[NextPoint Therapeutics @NextPointTX]

In Scrip’s “What Does 2026 Hold for Biopharma?” outlook, Tatiana Novobrantseva, CSO of NextPoint Therapeutics, shares her view on where oncology differentiation is headed, novel targets, deep biology, and modality-agnostic precision.

Read more: https://t.co/aSVg2KHAmg

[NextPoint Therapeutics @NextPointTX]

Clinical entry of NPX372, a first-in-class B7-H7–targeted T cell engager, following U.S. IND clearance.

The first-in-human study pairs an IgG-like CD3 bispecific with biomarker-driven patient selection to enable rapid clinical readouts in solid tumors.
https://t.co/387iPsgvDA

[NextPoint Therapeutics @NextPointTX]

A look at CEO Ivan Cheung presenting at the JP Morgan Conference. Ivan shared our precision oncology strategy across T cell engager, ADC and checkpoint inhibitor, grounded in B7-H7 science and biomarker-driven patient selection. Energized by conversations and year ahead.

[NextPoint Therapeutics @NextPointTX]

Jamie Strand, Ph.D., VP of Technical Operations, will speak at the CMC Strategy Forum North America on Jan 26, sharing how protein engineering and CMC-driven cell-line development support consistent, manufacturable B7-H7 biologics ready for the clinic. #CASSS #CMCNA2026

[NextPoint Therapeutics @NextPointTX]

Ivan Cheung, CEO of NextPoint Therapeutics, will present at the 2026 J.P. Morgan Healthcare Conference on Jan 15 at 8:30 am in San Francisco. NextPoint is advancing precision therapeutics across multiple modalities targeting B7-H7. 
#JPM2026

[NextPoint Therapeutics @NextPointTX]

Data from NextPoint Therapeutics at #AACR-NCI-EORTC!

NPX125, a B7-H7–targeting ADC, shows potent anti-tumor activity across solid tumor models.
Reinforcing the promise of B7-H7 as a next-generation ADC target.

[NextPoint Therapeutics @NextPointTX]

Headed to AACR-NCI-EORTC! Sr. Scientist Emilien Loeuillard will present a poster on NPX125, our novel ADC targeting B7-H7, a molecule central to tumor immune escape and highly expressed in tumors.

[NextPoint Therapeutics @NextPointTX]

Join NextPoint Chief Scientific Officer Tatiana Novobrantseva and Director, Research and Development Melissa Hayes, at #SITC25 where they will be presenting the poster:
TMIGD2 co-stimulation in a trispecific T cell engager elicits potent anti-tumor activity.

[NextPoint Therapeutics @NextPointTX]

Heading to the ADC Linker & Conjugation Summit? Catch NextPoint CSO Tatiana Novobrantseva, PhD, on Aug 20 as she shares unique attributes of NPX125, a DAR8 B7-H7 targeting ADC with a novel linker.

Can't make it? Let's connect!

[NextPoint Therapeutics @NextPointTX]

NextPoint CSO Tatiana Novobrantseva, PhD, will moderate a plenary panel at the #IOSummit on Aug 13: "Accelerating IO through Target Discovery." Proud to see B7-H7 biology and smart target selection front and center in solid tumor IO.

[NextPoint Therapeutics @NextPointTX]

NextPoint VP of Innovation Bijan Etemad-Gilbertson is heading to #BIO2025. We're advancing first-in-class precision therapeutic targeting the B7-H7 axis. Let’s connect in Boston to talk ADCs, TCEs & more.

[NextPoint Therapeutics @NextPointTX]

CSO Tatiana Novobrantseva is featured in Databird’s “30 Visioneers Shaping the Future of Biotech in 2025.” She shares how NextPoint’s B7-H7 pathway approach offers a new angle on immune activation beyond PD-L1.
Read more: https://t.co/36fWmHvbpX

[NextPoint Therapeutics @NextPointTX]

CMO Dr. Leena Gandhi, MD, PhD, speaks at Stanford's Stat4Onc Symposium on “Maintaining Flexibility in Dose Optimization in Early Phase Oncology Trials.” Don’t miss this expert-packed session on dose optimization across the drug lifecycle! #Stat4Onc #OncologyTrials

[NextPoint Therapeutics @NextPointTX]

#AACR2025 Recap: B7-H7-ADC NPX125
✅ Tumor-selective
✅Minimal normal tissue
✅High receptor density
Strong interest in NPX125’s targeting & proprietary linker tech.

[NextPoint Therapeutics @NextPointTX]

NextPoint to present pioneering preclinical data on NPX125, our B7-H7-targeted ADC, at #AACR2025. With proprietary linker tech + validated payload, NPX125 shows potent cytotoxicity + strong tumor activity.

Learn more: https://t.co/lr2lZNdo3t

[NextPoint Therapeutics @NextPointTX]

NextPoint Co-Founder Dr. Gordon Freeman, pioneer of PD-L1/PD-L2, will speak at the Festival of Biologics on antibody-based checkpoint inhibition. A true leader in cancer immunotherapy. #FestivalOfBiologics #Immunotherapy

[NextPoint Therapeutics @NextPointTX]

NextPoint is presenting 4 posters at #AACR2025! We're showcasing preclinical data on our B7-H7-targeted ADC and TCE programs. B7-H7 is upregulated across multiple cancer types with limited normal tissue expression— an ideal precision oncology target. https://t.co/45EaxnsCDl

[NextPoint Therapeutics @NextPointTX]

NextPoint Co-founder Dr. Gordon Freeman & CSO Dr. Tatiana Novobrantseva will be speaking at IO360. Check them out during the New Tech in Transformational Biology track. #IO360Summit